Overview

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on improvement in HbA1c.
Phase:
Phase 2
Details
Lead Sponsor:
XOMA (US) LLC
Treatments:
Metformin